Top
Dr Kohkan Shamsi, RadMD co-founder, has been confirmed as a speaker for RSNA 2022
Clinical Evidence Supports Dotarem® Injection for MR Imaging
RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent...
"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial"
JAMA Article on Gadolinium Exposure and Parkinson's: A False Sense of Safety? -Welk B, McArthur E, Marrow SA, et al. Association between Gadolinium contrast Exposure and the Risk of Parkinsonism
Deposition of Gadolinium in After Multiple GBCA Injections: Clinical Trial Prospective
Kohkan Shamsi, in collaboration with ICPME, develops an accredited course intended to educate on the potential implications of ordering and performing contrast-enhanced MRIs
RSNA 2014 Abstract: Evaluation of a New Manganese-based Orally-Administered Hepatobiliary MR Contrast Agent
RadMD Announces 2013 Webinar Series
RadMD Principal publishes in Nature Medicine
RadMD Receives Cum Laude Award at RSNA 2012
RadMD Expands Its Imaging Expertise Services with New European Office
RadMD Principals Publish in Clinical Leader
RadMD Principal publishes in Nature
Blinded Reader and Investigator Training Institute (BRITI) Announces Completion of First Accredited Course on Imaging in Cancer Clinical Trials
First Accredited Course on Imaging in Cancer Clinical Trials to be Hosted by Blinded Reader and Investigator Training Institute (BRITI)
On and Offsite Image Reads Is basing drug efficacy on the site read risky business?
Images: Read On Site or Centrally and Independently?
RadMD Offers Tips on Optimizing Clinical Trial Efficiency
RadMD reaches 150th clinical trial
